New Whitepaper: Origination in the Age of AI–How signal-driven infrastructure is replacing broker-dependent deal flow.Read now↗

Transaction Intelligence
Transactions
Closed & announced M&A across every sector and state.
Sectors
Browse transactions by industry vertical.
States
Browse transactions by U.S. state.
Buyers
Browse transactions by acquiring company.
On-marketComing soon
Businesses actively listed for sale.
PE Firms M&A Firms Commercial Lenders Investment Banks
Deal Origination
End-to-end outreach infrastructure that sources proprietary deal flow.
Data & Research
TAM mapping, data enrichment, custom scraping, and automated research.
AI Implementation
How Tentt deploys AI across your deal origination stack.
Resources
Playbooks
Channel-specific outreach playbooks for deal origination.
All research
Comparison posts, methodology, and analysis from the Tentt team.
Reports
Monthly market reports on M&A and private equity activity.
Tools
Free calculators for M&A, lending, and deal analysis.
Whitepaper↗
Origination in the Age of AI.
About
Book an intro call

Gilead Sciences — Acquisitions & M&A Deals

4 deals

Tracking 4 M&A deals by Gilead Sciences.

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

HealthcareBolt-on

Gilead Sciences→Tubulis

Apr 7, 2026

T/A - GILEAD SCIENCES, INC. (0000882095) (Filed by) — SEC SC TO Filing

HealthcareCaliforniaMerger

Gilead Sciences→Arcellx

Apr 1, 2026

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio - Proactive financial news

HealthcareOther

Gilead Sciences→Ouro Medicines

Mar 24, 2026

Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive

HealthcareMerger

Gilead Sciences→Arcellx

Feb 23, 2026